NeuroPace, Inc. Stock News

NeuroPace, Inc. (NPCE) CEO Mike Favet on Q4 2021 Results - Earnings Call Transcript

MOUNTAIN VIEW, Calif., Jan. 27, 2022 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy,

NeuroPace <> expects prelim. Q4 unaudited revenue of ~$11M, up 2% from $10.8M in Q4 2020. Prelim

MOUNTAIN VIEW, Calif., Jan. 11, 2022 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (NASDAQ: NPCE ), a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy, today announced its preliminary, unaudited revenue for the fourth quarter and full-year ended December 31, 2021. Based on available financial information, preliminary unaudited fourth quarter 2021 revenue is expected to be approximately $11.0 million, compared to $10.8 million in the fourth quarter in the prior year period, reflecting growth of 2%. Initial implant revenue for the fourth quarter 2021 is expected to be approximately $8.5 million, compared to $7.7 million in the fourth quarter 2020, reflecting growth of 10%. Replacement implant revenue for the fourth quarter 2021 is expected to be approximately $2.5 million, compared to $3.1 million in the fourth quarter 2020, reflecting a decline of 19%. Based on available financial information, preliminary unaudited full-year 2021 revenue is expected to be approximately $45.2 million, compared to $41.1 million in full year 2020, reflecting growth of 10%.

NeuroPace Inc (NPCE) shares closed today 13.2% lower than it did at the end of yesterday. The stock is currently down 0.4% year-to-date, down 59.8% over the past 12 months, and down 59.8% over the past five years. Today, the Dow Jones Industrial Average fell 0.0%, and the S&P 500 fell 0.4%. Trading Activity Shares traded as high as $11.82 and as low as $9.71 this week.Shares closed 63.3% below its 52-week high and 21.1% above its 52-week low.Trading volume this week was 67.4% lower than the 10-day average and 41.3% lower than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.0. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price lags the S&P 500 Index today, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price lags the Dow Jones Industrial Average today, lags it on a 1-year basis, and lags it on a 5-year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -95.4% The company's stock price performance over the past 12 months lags the peer average by 334.9% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

MOUNTAIN VIEW, Calif., Dec. 16, 2021 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy, today announced that Mike Favet, CEO, Rebecca Kuhn, CFO and VP of Finance and Administration, and Irina Ridley, General Counsel and Corporate Secretary will present virtually at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12th, 2022, at 8:15 am Pacific Time / 11:15am Eastern Time.

MOUNTAIN VIEW, Calif., Dec. 16, 2021 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy,

Gainers Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ) shares jumped 80.4% to close at $90.08 on Monday. Pfizer agreed to acquire Arena Pharmaceuticals for $100 per share in an all-cash transaction. Foghorn Therapeutics Inc. (NASDAQ: FHTX ) shares jumped 55% to close at $18.58. Loxo Oncology, an R&D group of Eli Lilly And Co (NYSE: LLY ), and Foghorn Therapeutics collaborated to create oncology medicines by applying Foghorn''s Gene Traffic Control platform. BELLUS Health Inc. (NASDAQ: BLU ) gained 48.2% to settle at $8.30 after the company announced topline data its Phase 2b SOOTHE trial of BLU-5937 in Refractory Chronic Cough. Petros Pharmaceuticals, Inc. (NASDAQ: PTPI ) surged 47.4% to close at $3.98 after gaining more than 14% on Friday. Energy Focus, Inc. (NASDAQ: EFOI ) gained 36.2% to close at $4.70. East Stone Acquisition Corporation (NASDAQ: ESSC ) jumped 31.4% to close at $18.40 after gaining over 8% on Friday. Puxin Limited (NYSE: NEW ) climbed 27.1% to settle at $0.41 after tumbling over 10% on Friday.

New Jersey, United States,- Verified Market Research has recently published a research report titled, Sacral Nerve Stimulation Market Size, and Forecast 2021-2028, Breakdown Data by Manufacturers, Key Regions, Types and Application. Primary and secondary research methodologies have been used to

NeuroPace, Inc. (NASDAQ:NPCE) has been assigned a consensus rating of “Buy” from the six analysts that are currently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation and four have issued a buy recommendation on the company. The average twelve-month price objective […]

Northern Trust Corp acquired a new stake in NeuroPace, Inc. (NASDAQ:NPCE) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 71,277 shares of the companys stock, valued at approximately $1,696,000. Northern Trust Corp owned 0.29% of NeuroPace as of its []

NeuroPace, Inc. (NASDAQ:NPCE) Investment analysts at SVB Leerink cut their FY2021 earnings per share estimates for shares of NeuroPace in a research note issued on Wednesday, November 10th. SVB Leerink analyst D. Antalffy now expects that the company will post earnings of $9.67 per share for the year, down from their previous forecast of []

JPMorgan Chase & Co. acquired a new stake in NeuroPace, Inc. (NASDAQ:NPCE) during the second quarter, according to its most recent Form 13F filing with the SEC. The fund acquired 7,993 shares of the companys stock, valued at approximately $191,000. Several other large investors have also made changes to their positions in NPCE. Bellevue Group []

SVB Leerink reaffirmed their buy rating on shares of NeuroPace (NASDAQ:NPCE) in a research note published on Sunday, AnalystRatings.com reports. SVB Leerink currently has a $30.00 price objective on the stock. SVB Leerink also issued estimates for NeuroPaces FY2021 earnings at $9.67 EPS, Q1 2022 earnings at ($0.35) EPS, Q2 2022 earnings at ($0.37) EPS, []

NeuroPace (NASDAQ:NPCE) had its price objective cut by Wells Fargo & Company from $28.00 to $20.00 in a report released on Thursday, The Fly reports. They currently have an overweight rating on the stock. Other research analysts have also issued reports about the company. Robert W. Baird began coverage on NeuroPace in a research report []